INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Summit Therapeutics Inc. and its officers or directors following disappointing clinical trial results for its drug ivonescimab [1][3]. Group 1: Company Overview - Summit Therapeutics Inc. is a publicly traded company on NASDAQ under the ticker SMMT [1]. - The company recently announced topline results from its Phase III clinical trial, HARMONi, evaluating ivonescimab [3]. Group 2: Clinical Trial Results - The Phase III trial indicated that patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die compared to those receiving chemotherapy alone [3]. - However, the drug did not show a statistically significant difference in overall survival, which measures the duration patients live before dying from any cause [3]. Group 3: Market Reaction - Following the announcement of the clinical trial results, Summit's stock price dropped by $7.99 per share, representing a 30.5% decline, closing at $18.22 per share on May 30, 2025 [4].